CordenPharma, a leading global pharmaceutical CDMO, announced the appointment of Dr. Jean-Luc Herbeaux as Chief Executive Officer, effective 1 October 2026, as the company enters its next phase of growth.
Dr. Herbeaux will succeed Dr. Michael Quirmbach, who has served as CordenPharma's Chief Executive Officer since 2019 and has played a defining role in the company's growth and transformation over the past 12 years. As part of the planned leadership transition, Michael will remain actively involved with CordenPharma as a Board Member and Senior Advisor, bringing his deep knowledge of the company and industry expertise and providing strategic guidance as the company enters its next phase.
Dr. Jean-Luc Herbeaux appointed Chief Executive Officer
Dr. Herbeaux joins CordenPharma from Hovione, an international CDMO, where he served as Chief Executive Officer for more than four years. Prior to becoming CEO, he served as Chief Operating Officer at Hovione and previously held several senior roles at Evonik, a global leader in specialty chemicals and sustainable material technologies.
As Chief Executive Officer, Dr. Herbeaux will lead the execution of CordenPharma's long-term strategy, working closely with the Board and with the continued support of Astorg, with a focus on continued growth, operational execution, customer delivery and the further development of the company's global platform.